3,3-二甲基-2-氧杂-7-氮杂螺[4.5]癸-1-酮 | 1263283-85-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 3,3-二甲基-2-氧杂-7-氮杂螺[4.5]癸-1-酮
• 英文名称: 3,3-dimethyl-2-oxa-7-azaspiro[4.5]decan-1-one
• 英文别名: 3,3-dimethyl-2-oxa-9-azaspiro[4.5]decan-1-one
• CAS: 1263283-85-7
• 化学式: C₁₀H₁₇NO₂
• 分子量: 183.25
• InChiKey: JKQWHHIQKQXWOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3,3-二甲基-2-氧杂-7-氮杂螺[4.5]癸-1-酮 在 盐酸 、 水 、 三乙酰氧基硼氢化钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 7-{1-[(2-amino-1-benzothiophen-3-yl)carbonyl]piperidin-4-yl}-3,3-dimethyl-2-oxa-7-azaspiro[4.5]decan-1-one
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors

  摘要：

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.117
• 作为产物：
  描述：

  N-Boc-3-哌啶甲酸乙酯 在 盐酸 、 水 、 臭氧 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 2.0h， 生成 3,3-二甲基-2-氧杂-7-氮杂螺[4.5]癸-1-酮
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors

  摘要：

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.117

文献信息

• [EN] IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE PRÉSENTANT DES PROPRIÉTÉS ANTAGONISTES DU A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2019118313A1

  公开（公告）日：2019-06-20

  Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: "Z" and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

  本文披露了具有Formula I结构的化合物，或者其任何药学上可接受的盐：其中：“Z”和R1在此有定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度发现的受体。据信，这些化合物和药物配方在治疗或管理神经退行性疾病，例如帕金森病，或由于使用治疗或管理帕金森病的某些药物而引起的运动障碍方面是有用的。
• SPIRO-CYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1911753A1

  公开（公告）日：2008-04-16

  The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

  本发明提供了一种由以下式（I）表示的化合物： 其中 E是一个可选择地取代的环状基团； D是一个羰基团或磺酰基团； A是CH或N； 环P是一个可选择进一步取代的5至7元环； 环Q是一个可选择进一步取代的5至7元非芳香环； 环R是一个可选择进一步取代和可选择缩合的5至7元非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等的预防或治疗具有用处，并且在功效、持续活性、特异性、低毒性等方面具有优越性能。
• Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors
  作者：Tohru Yamashita、Makoto Kamata、Satoshi Endo、Mitsuo Yamamoto、Keiko Kakegawa、Hiroyuki Watanabe、Katsuhiko Miwa、Toru Yamano、Masaaki Funata、Jyun-ichi Sakamoto、Akiyoshi Tani、Clifford D. Mol、Hua Zou、Douglas R. Dougan、BiChing Sang、Gyorgy Snell、Kohji Fukatsu

  DOI：10.1016/j.bmcl.2011.08.117

  日期：2011.11

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.